Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments

3 days ago 8
Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.
Read Entire Article
  1. Homepage
  2. category-label-
  3. Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments

Related

How to find purpose and passion in retirement without a title, salary or to-do list

How to find purpose and passion in retirement without a titl...

9 minutes ago 0
How you can keep your job as Trump and Google propel AI spending

How you can keep your job as Trump and Google propel AI spen...

52 minutes ago 0
Intel earnings bring more questions than answers, sending the stock lower

Intel earnings bring more questions than answers, sending th...

1 hour ago 3

Trending

1. lori vallow
2. olivia rodrigo
3. maria sakkari
4. ben stokes
5. tomi lahren
6. hims stock
7. brendan donovan
8. morocco
9. maldives
10. michael ward

Popular

Airport lounges are ‘ridiculously crowded.’ New mini lounges might help ease the traffic.

Airport lounges are ‘ridiculously crowded.’ New mini lounges...

6 days ago 64
Trump signs the Genius Act into law, in significant step for U.S. crypto regulation

Trump signs the Genius Act into law, in significant step for...

6 days ago 52
Hacker reconnaissance work continues on TeleMessage app vulnerability — Report

Hacker reconnaissance work continues on TeleMessage app vuln...

6 days ago 51
Why cheaper power looks unlikely as Trump’s big budget law reshuffles the U.S. energy landscape

Why cheaper power looks unlikely as Trump’s big budget law r...

6 days ago 43
My ex-husband’s benefit will be $2,600 at retirement age, and mine is $2,200. Can I claim on his record instead? 

My ex-husband’s benefit will be $2,600 at retirement age, an...

5 days ago 42
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Tayedi Search engine 2025. All rights are reserved